SAR445877A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Sponsor:

Sanofi

Code:

NCT05584670

Conditions

Solid Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

SAR445877

Cetuximab

ADG126

Bevacizumab

Nivolumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-02. This information was provided to ClinicalTrials.gov by Sanofi on 2026-06-23.